Non-platinum single agent in partially platinum-sensitive
(TFIp 6-12 m) is inferior to platinum combination
0.00
0.25
0.50
0.75
1.00
Probability of Overall Survival
107 90
71
52
34
23
13
10
6
5
5
1
1
NPBC->PBC
108 102 92
70
45
31
21
16
10
5
3
3
3
PBC->NPBC
Number at risk
0
6
12
18
24
30
36
42
48
54
60
66
72
Months
Arm
Median
(m)
95%CI
PBC-
>NPBC
24.5
22.4-
33.6
NPBC-
>PBC
21.8
16.3-
29.3
Adjusted* HR 1.38; 95%CI 0.99-
1.94 p=0.06
* By line of treatment, residual
disease and size of centre
R
A
N
D
O
M
1:1
NPBC**
PBC*
PD
NPBC
PBC
PD
*Pt-based Chemotherapy:
• Carboplatin + Paclitaxel or
• Carboplatin + Gemcitabine
(in case of neurotoxicity at
baseline)
**Non-Pt-Based Chemotherapy:
• PLD or other approved single
agents
Primary Endpoint: Overall Survival
MITO-8
S. Pignata et al. ASCO 2016
